Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 1.00 |
| ▸ | ESR1 | P03372 | 7/20 | 0.83 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.83 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.83 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.83 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.83 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.83 |
| ▸ | MAOA | P21397 | 1/20 | 0.83 |
| ▸ | PDE5A | O76074 | 1/20 | 0.83 |
| ▸ | ACHE | P22303 | 3/20 | 0.76 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.68 |
| ▸ | PRKCA | P17252 | 1/20 | 0.68 |
| ▸ | BACE1 | P56817 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sophoraflavanone A SCHEMBL29624617 | 1.00 | ABCG2 (1.00) | ABCG2ESR1ESR2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL147316 | 0.91 | ESR1 (1.00) | ABCG2ESR1ESR2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL14304885 | 0.91 | ESR1 (1.00) | ABCG2ESR1ESR2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL29396586 | 0.91 | ESR1 (1.00) | ABCG2ESR1ESR2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL1171435 | 0.91 | ESR1 (1.00) | ABCG2ESR1ESR2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL1931652 | 0.90 | ESR1 (0.98) | ABCG2ESR1ESR2AKR1B10AKR1B1 | |
| SCHEMBL17626647 | 0.89 | ABCG2 (0.79) | ABCG2ESR1ESR2AKR1B10AKR1B1 | |
| SCHEMBL27013448 | 0.89 | ABCG2 (0.79) | ABCG2ESR1ESR2AKR1B10AKR1B1 | |
| SCHEMBL29808777 | 0.89 | ABCG2 (0.79) | ABCG2ESR1ESR2AKR1B10AKR1B1 | |
| SCHEMBL17626644 | 0.89 | ABCG2 (0.79) | ABCG2ESR1ESR2AKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046469-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | KUHRTS ERIC HAUSER (US) | 2019-02-14 | — | — | US | claimed |
| US-20150209307-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | KUHRTS ERIC HAUSER (US) | 2015-07-30 | — | — | US | claimed |
| WO-2014025989-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | KUHRTS ERIC HAUSER (US) | 2014-02-13 | — | — | WO | claimed |
| US-20140045904-A1 | NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT | KUHRTS ERIC HAUSER (US) | 2014-02-13 | — | — | US | claimed |
| WO-2012051107-A2 | NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE-EFFECT | KUHRTS ERIC HAUSER (US) | 2012-04-19 | — | — | WO | claimed |
| US-20120059052-A1 | PRENYLFLAVONOID FORMULATIONS | BIOACTIVES, INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20110003888-A1 | HOPS EXTRACTION METHODS AND MIXTURES | BIOACTIVES, INC. (US) | 2011-01-06 | — | — | US | claimed |
| US-20090209654-A1 | Prenylflavonoid Formulations | BIOACTIVES, INC. | 2009-08-20 | — | — | US | claimed |
| WO-2008095189-A1 | METHODS AND COMPOSITIONS FOR TREATING DYSLIPIDAEMIA | BIOACTIVES, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| WO-2008089137-A1 | HOPS EXTRACTION METHODS AND MIXTURES | BIOACTIVES, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| EP-1909584-A2 | PRENYLFLAVONOID FORMULATIONS | Bioactives, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| US-20070218155-A1 | Methods and compositions for treating dyslipidaemia | BIOACTIVES, INC. | 2007-09-20 | — | — | US | claimed |
| WO-2007053915-A2 | NARINGENIN DERIVATIVES WITH SELECTIVITY ON ERS | UNIVERSITEIT GENT (BE) | 2007-05-18 | — | — | WO | claimed |
| WO-2007016578-A2 | PRENYLFLAVONOID FORMULATIONS | BIOACTIVES, INC. (US) | 2007-02-08 | — | — | WO | claimed |
| US-20050019438-A1 | Hop extracts and use thereof in the production of a medicament having estrogenic properties | BOURGES-SEVENIER CEDRIC (FR) | 2005-01-27 | — | — | US | claimed |
| EP-1381379-A1 | HOP EXTRACTS AND USE THEREOF IN THE PRODUCTION OF A MEDICAMENT HAVING ESTROGENIC PROPERTIES | BERKEM (FR) | 2004-01-21 | — | — | EP | claimed |
| WO-2002085393-A1 | HOP EXTRACTS AND USE THEREOF IN THE PRODUCTION OF A MEDICAMENT HAVING ESTROGENIC PROPERTIES | BERKEM (FR) | 2002-10-31 | — | — | WO | claimed |
| US-20240091279-A1 | COMBINATION THERAPY FOR INFLAMMATORY DISEASES | NATIONAL INSTITUTES OF HEALTH | 2024-03-21 | — | — | US | disclosed |
| WO-2003014287-A1 | HOPS EXTRACTS, METHOD FOR THE PRODUCTION AND USE | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002085393-A1 | HOP EXTRACTS AND USE THEREOF IN THE PRODUCTION OF A MEDICAMENT HAVING ESTROGENIC PROPERTIES | BERKEM (FR) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059052-A1 | PRENYLFLAVONOID FORMULATIONS | TP53, CYP46A1, HPGD | ABCG2 110/4885ESR1 1771/4885ESR2 1616/4885 |
| US-20150209307-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | CUTA, PSEN2, PNN | ABCG2 4834/4885ESR1 421/4885ESR2 713/4885 |
| US-20190046469-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | CUTA, PSEN2, PNN | ABCG2 4834/4885ESR1 421/4885ESR2 713/4885 |
| US-20110003888-A1 | HOPS EXTRACTION METHODS AND MIXTURES | HMGB2, HMGB3, HPGDS | ABCG2 2079/4885ESR1 752/4885ESR2 599/4885 |
| US-20140045904-A1 | NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT | NAPRT, NISCH, NAMPT | ABCG2 549/4885ESR1 2279/4885ESR2 3047/4885 |
| US-20090209654-A1 | Prenylflavonoid Formulations | TP53, CYP46A1, HPGD | ABCG2 110/4885ESR1 1771/4885ESR2 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.